We provide a highly efficient, DNA-encoded epitope library for rapid T cell-based reporter gene assays. This system significantly reduces research costs while enabling the screening of thousands of samples in a single, streamlined process.
Creative Biolabs provides a powerful and precise solution for evaluating T cell function. Our platform is engineered to deliver specific, actionable data that directly addresses the core challenges in immuno-oncology research, from target identification to therapy validation. Creative Biolabs provides clear, quantitative measurements of T cell activation in response to a wide range of stimuli, including small molecules, biologics, and cellular antigens.
Reporter gene-encoded protein is used by researchers to indicate the expression of the gene of interest, expressed naturally or a transgenic gene fusion to the target genome, successfully. The reporter gene is widely employed in various studies on cell-level and animal levels to explain the complex process. IL-2 secretion is a selective marker for activated T cells and is often used as an indicator of antigen-specific T cell activation. Other reporter genes, such as GFP and luciferase, are integrated under the control of human promoters to monitor T cell responses.
To explore how our specialized expertise can benefit your project - Request a consultation.
We provide a highly efficient, DNA-encoded epitope library for rapid T cell-based reporter gene assays. This system significantly reduces research costs while enabling the screening of thousands of samples in a single, streamlined process.
Our platform allows for the simultaneous testing of MHC class I and II with various HLA alleles. This, combined with next-generation sequencing, provides a full, comprehensive analysis of antigenic epitopes.
We eliminate the complexity of endogenous T cell receptors by using proprietary TCR-knockout Jurkat cell lines. This results in cleaner, more reliable data with a higher signal-to-noise ratio.
Our platform extends beyond drug screening, enabling the selection of immunogenic epitopes from pathogens, the isolation of specific T cells, and the identification of epitope-binding TCR sequences.
Creative Biolabs provides various bioassays for cancer epitope analysis and assessment. Here, we present a reporter gene-based T-cell assay to identify class I- and class II-restricted epitopes.
Partner with our dedicated team of experts to accelerate your immuno-oncology research. We are committed to providing superior specificity, reliability, and high-throughput capabilities to help you achieve your project goals efficiently and confidently.
Our service stands out by utilizing proprietary TCR-KO cell lines and advanced dual-reporter systems. These technologies are engineered to deliver data that is far more accurate and meaningful than what is possible with conventional assay methods.
We have specifically designed our platform to eliminate common challenges like false positives and background noise. This ensures that every readout is a cleaner and more precise signal, giving you a higher degree of confidence in your results.
Our robust systems offer superior specificity and reliability. This means you can trust our data to be both reproducible and actionable, empowering you to make critical decisions with confidence throughout your drug discovery and development pipeline.
Discover how a partnership with us can streamline your research - Get a quote today.
Our reporter gene assays offer superior sensitivity and are more amenable to high-throughput screening. The assays provide a real-time, quantitative readout of an early T cell signaling event, allowing for more precise data on compound potency and kinetics.
Our advanced dual-reporter system is specifically designed to address this concern. The second, constitutively expressed reporter provides an internal control for cell viability, allowing us to normalize the primary signal and distinguish between true inhibition and compound cytotoxicity.
We provide comprehensive services for the design, generation, and functional characterization of engineered T cells, including CAR-T and TCR-T cell therapies.
Learn More →We provide a comprehensive service for assessing the functional activity of immune checkpoint inhibitors, including PD-1, PD-L1, and CTLA-4. Our assays are ideal for preclinical studies and for guiding the development of novel antibodies.
Learn More →Creative Biolabs is an oncology research consultancy and experimental service provider. With many years of experience in cancer study, Creative Biolabs offers clients the most suitable solutions with premium quality and efficiency. Please contact us for more information.